Why Are Shares Of ADMA Biologics Falling Today?

ADMA Biologics, Inc. (NASDAQ:ADMA) shares are tumbling on Thursday after Cantor Fitzgerald downgraded the stock to Neutral. ADMA Biologics shares are approaching critical lows. What’s behind ADMA weakness? ADMA Gets Hit With Short Seller Report Cantor Fitzgerald analyst Kristen Kluska downgraded ADMA Biologics from Overweight to Neutral following a short-seller report from earlier this week. Culper Research released a report, alleging that ADMA Biologics has been misrepresenting its financial results and operating metrics. The company responded to the report on Wednesday, calling it “speculative” and based on “unreliable sources.” “The Short Report … appears premised on speculative assertions derived from unidentified and unreliable sources and contains numerous misleading, false and inaccurate statements,” the company said. With Thursday’s decline, ADMA Biologics stock is down about 47% this week and has fallen nearly 60% over the past three months. ADMA Shares Trade Well Below Key Averages ADMA is trading 46.7% below its 20-day simple moving average (SMA) and 52.9% below its 100-day SMA, keeping both the short- and intermediate-term trend pointed down. Shares are down 59.49% over the past 12 months and are now sitting closer to their 52-week lows than highs after setting a new 52-week low on 2026-03-26. Momentum gauges are stretched: RSI is at 19.58, which is deeply oversold and often signals capitulation risk rather than "healthy" weakness. Meanwhile, MACD is at -1.1055 versus a signal line of -0.5828, keeping bearish momentum in control with a negative histogram of -0.5227. The combination of oversold RSI (below 30) and bearish MACD suggests mixed momentum, where selling pressure is dominant even as a bounce risk starts to rise. Key Resistance: $15.00 Key Support: $8.00 ADMA Shares Fall Thursday ADMA Stock Price Activity: ADMA Biologics shares were down 17.76% at $7.94 at the time of publication on Thursday, according to Benzinga Pro data. Image: Shutterstock